A RANDOMIZED TRIAL OF OBSERVATION VERSUS RADIOTHERAPY IN PRIMARY MEDIASTINAL B‐CELL LYMPHOMA PATIENTS WITH COMPLETE METABOLIC RESPONSE AFTER STANDARD IMMUNOCHEMOTHERAPY.

Authors :: Davies, A. J.
Zucca, E.
Ceriani, L.
Kryachok, I.
Ciccone, G.
Botto, B.
Balzarotti, M.
Tucci, A.
Rusconi, C.
Usai, S. V.
Pennese, E.
Arcaini, L.
Dabrowska‐Iwanicka, A.
Ferreri, A. J. M.
Merli, F.
Zhao, W.
Hodgson, D.
Rigacci, L.
Cellini, C.
Stelitano, C.
Source :: Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p48-50, 3p
Publication Year :: 2023
Abstract: The IELSG37 (NCT01599559) randomized trial was planned with a non-inferiority design to test whether RT can be omitted in PMBCL patients who achieve a complete metabolic response (CMR) after immunochemotherapy. Mediastinal radiotherapy (RT) may consolidate responses to dose-intensive immunochemotherapy; however, it increases the risk of second malignancies and coronary or valvular heart disease. B Introduction: b Primary mediastinal B-cell lymphoma (PMBCL) has a poor prognosis if remission is not rapidly achieved, or the disease recurs. [Extracted from the article]

Full Text Access

Tools